Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial.

[1]  C. Yalçınkaya,et al.  Beneficial Effects of Everolimus on Autism and Attention-Deficit/Hyperactivity Disorder Symptoms in a Group of Patients with Tuberous Sclerosis Complex. , 2017, Journal of child and adolescent psychopharmacology.

[2]  A. Byars,et al.  Influence of seizures on early development in tuberous sclerosis complex , 2017, Epilepsy & Behavior.

[3]  A. Wilfong,et al.  Long-term treatment of epilepsy with everolimus in tuberous sclerosis , 2016, Neurology.

[4]  J. Osborne,et al.  Causes of mortality in individuals with tuberous sclerosis complex , 2017, Developmental medicine and child neurology.

[5]  G. Kasprian,et al.  Efficacy and safety of Everolimus in children with TSC - associated epilepsy – Pilot data from an open single-center prospective study , 2016, Orphanet Journal of Rare Diseases.

[6]  J. French,et al.  Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study , 2016, The Lancet.

[7]  D. Rizopoulos,et al.  Sirolimus for epilepsy in children with tuberous sclerosis complex , 2016, Neurology.

[8]  P. Curatolo,et al.  Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex. , 2015, Seminars in pediatric neurology.

[9]  P. J. Vries,et al.  Neurological and neuropsychiatric aspects of tuberous sclerosis complex , 2015, The Lancet Neurology.

[10]  J. Sampson,et al.  Epilepsy in Tuberous Sclerosis: Phenotypes, Mechanisms, and Treatments , 2015, Seminars in Neurology.

[11]  P. Curatolo.  Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. , 2015, Pediatric neurology.

[12]  A. Vignoli,et al.  Epilepsy in TSC: Certain etiology does not mean certain prognosis , 2013, Epilepsia.

[13]  A. Wilfong,et al.  Treating Epilepsy in Tuberous Sclerosis with Everolimus: Getting Closer , 2014, Epilepsy currents.

[14]  K. Kotulska,et al.  Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. , 2013, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[15]  David Chen,et al.  Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[16]  E. Thiele,et al.  Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial , 2013, The Lancet.

[17]  S. Jóźwiak,et al.  Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations. , 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[18]  D. Roberts,et al.  Epilepsy surgery in tuberous sclerosis: a review. , 2012, Neurosurgical focus.

[19]  P. Curatolo,et al.  Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis , 2011, Epilepsy & Behavior.

[20]  A. Byars,et al.  Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. , 2010, The New England journal of medicine.

[21]  P. Curatolo,et al.  Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges , 2010, Child's Nervous System.

[22]  P. Curatolo,et al.  Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. , 2010, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[23]  S. Camposano,et al.  The natural history of epilepsy in tuberous sclerosis complex , 2009, Epilepsia.

[24]  P. Curatolo,et al.  Can we change the course of epilepsy in tuberous sclerosis complex? , 2009, Epilepsia.

[25]  D. Gutmann,et al.  Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex , 2008, Annals of neurology.

[26]  J. Peiris,et al.  Pneumonia research to reduce childhood mortality in the developing world. , 2008, The Journal of clinical investigation.

[27]  M. Delgado,et al.  Seizure remission and antiepileptic drug discontinuation in children with tuberous sclerosis complex. , 2003, Archives of neurology.

[28]  O. Dulac,et al.  Topographic Comparative Study of Magnetic Resonance Imaging and Electroencephalography in 34 Children with Tuberous Sclerosis , 1990, Epilepsia.

[29]  J. Stockman,et al.  Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis , 2012 .